| Developer | Country | Clinical Trial Phase | Strategy |
| CanSino Biological Inc./Beijing Institute of Biotechnology | China | I and II | Non-replicating viral vector |
| Beijing Institute of Biological Products/ Wuhan Institute of Biological Products | China | I | Inactivated virus |
| Sinovac | China | I | Inactivated virus |
| University of Oxford | UK | I | Non-Replicating Viral Vector |
| BioNTech/Fosun Pharma/Pfizer | USA | I | RNA |
| Moderna/NIAID | USA | I | RNA |
| Inovio Pharmaceutical | USA | I | DNA |